Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

DSpace Repositorium (Manakin basiert)

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

Autor(en): Barbour, Thomas; Scully, Marie; Ariceta, Gema; Cataland, Spero; Garlo, Katherine; Heyne, Nils; Luque, Yosu; Menne, Jan; Miyakawa, Yoshitaka; Yoon, Sung-Soo; Kavanagh, David
Tübinger Autor(en):
Heyne, Nils
Erschienen in: Kidney International Reports (2021), Bd. 6, H. 6, S. 1603-1613
Verlagsangabe: Elsevier Science Inc
Sprache: Englisch
Referenz zum Volltext: http://dx.doi.org/10.1016/j.ekir.2021.03.884
ISSN: 2468-0249
DDC-Klassifikation: 610 - Medizin, Gesundheit
Dokumentart: Wissenschaftlicher Artikel
Zur Langanzeige

Das Dokument erscheint in: